In the application of assisted reproductive technology（ART），the impact of antinuclear antibody（ANA）on the pregnancy outcomes of infertile patients has garnered attention. ANA，as a biomarker of autoimmune abnormalities，has been extensively studied for its association with unexplained infertility and its potential effects on oocyte and embryo quality. Current evidence suggests that a positive ANA status may be associated with reduced ovarian reserve function，poor embryo development，decreased clinical pregnancy rates，and increased risk of miscarriage. The level of ANA in follicular fluid is considered a sensitive indicator for predicting autoimmunity-related infertility. Specific ANA subtypes，such as anti -dsDNA antibodies and anti -centromere antibodies（ACA），are related to oocyte maturation disorder and delayed embryo development. Nevertheless，the direct link between a positive ANA status and the decline in female fertility and adverse reproductive outcomes requires further research for clarification. The review also discusses various treatment options for ANA-positive patients，including glucocorticoids，low-dose aspirin，and hydroxychloroquine， aiming to provide guidance for clinical practice and research in ART.